caffeine + omeprazole + warfarin

This cocktail of CYP450 substrates is a combination of caffeine, omeprazole, and warfarin used as a clinical tool to evaluate drug-drug interactions (DDI). Specifically, it serves as a probe for the metabolic activity of the enzymes Cytochrome P450 1A2 (CYP1A2), 2C19 (CYP2C19), and 2C9 (CYP2C9). In clinical pharmacology studies conducted by Galapagos NV, this cocktail was used to assess the impact of the investigational drug GLPG1205 on these specific metabolic pathways in healthy subjects. The cocktail allows for the simultaneous evaluation of multiple CYP450 isoforms, providing a comprehensive profile of a test compound's potential to inhibit or induce key drug-metabolizing enzymes. By measuring the pharmacokinetic profiles of these substrates when administered with and without the test compound, researchers can determine the potential for metabolic drug interactions.

Other names

CYP450 substrate cocktailCYP-450 substrate cocktailCYP 450 substrate cocktailCYP1A2/2C19/2C9 substrate cocktailcocktail of CYP450 substrates